Sartorius Stedim finalizes the acquisition of the British Albumedix | Photo credits: Sartorius Stedim
PARIS (Agefi-Dow Jones)–Pharmaceutical industry supplier Sartorius Stedim Biotech announced on Friday that it has completed the acquisition of Albumedix.
The group had reached an agreement in early August to buy this British company for 415 million pounds sterling (about 472 million euros) from private investors.
Albumedix specializes in recombinant human albumin, “a critical component in the manufacture of innovative biopharmaceuticals, particularly for modalities such as cell or viral therapies and vaccines,” Sartorius Stedim said at the time.
Based in Nottingham, the company has more than 100 employees and is expected to achieve revenue of around £33m in 2022, and a double-digit EBITDA margin.
-Francois Schott, Agefi-Dow Jones; 01 41 27 47 92; [email protected] ed: JEB
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
September 30, 2022 11:11 ET (15:11 GMT)